Closed-Loop CSF Circulation for Targeted ASO Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for intrathecal drug delivery face challenges in ensuring accurate targeting and real-time dosage verification of drugs to specific brain anatomy, as well as controlling drug concentration in the surrounding fluid.
Innovation Solution
A method involving a fluid channel connecting the lumbar region and the brain ventricle, with a pump and antisense oligonucleotide material, allows for controlled cerebrospinal fluid (CSF) flow and drug distribution, utilizing a closed loop system to circulate CSF and therapeutic materials, enabling localized treatment while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If intrathecal drug delivery is performed using conventional methods, then drug administration is simplified, but accurate targeting and real-time dosage verification to specific brain anatomy cannot be ensured
Solution Approach 1:
The patent incorporates sensors to detect drug concentration and flow rate in real-time, providing feedback to a control system that adjusts pump operation accordingly. This enables precise dosage verification and targeting while maintaining manageable system complexity through automated control.
Solution Approach 2:
The patent replaces conventional mechanical injection systems with a pump-based fluid delivery system controlled by electronic sensors and a control circuit. This substitution enables precise measurement and control of drug delivery parameters that cannot be achieved with traditional mechanical methods.
2Measurement precision
If conventional intrathecal delivery is used, then the delivery process is simpler, but real-time control of drug concentration in surrounding fluid is not possible
Solution Approach 1:
Sensors continuously monitor drug concentration in the CSF and provide feedback to the control system, which automatically adjusts pump operation to maintain target concentration levels. This enables real-time concentration control while the system operates autonomously.
Solution Approach 2:
The system automatically regulates its own operation by using sensor feedback to control the pump, eliminating the need for manual adjustment. The system self-adjusts to maintain desired drug concentration, simplifying operation while enabling precise control.
3Reliability
If therapeutic agents are delivered to the brain, then treatment effectiveness is improved, but toxicity and the need for large drug volumes increase
Solution Approach 1:
The patent uses flow direction control to direct CSF and therapeutic agents to specific target regions in the brain, ensuring concentrated delivery at the site of action. This localized approach improves treatment effectiveness while minimizing exposure to non-target areas, reducing overall toxicity.
Solution Approach 2:
The system dynamically adjusts flow rate and pump operation parameters to optimize drug delivery. By controlling the rate and timing of drug administration, the system achieves effective treatment concentrations at target sites while minimizing total drug volume and associated toxicity.
4Stability of the object's composition
If pump is continuously energized to maintain CSF flow, then drug delivery consistency is improved, but energy consumption increases
Solution Approach 1:
The pump operates in periodic cycles rather than continuously, activating only when needed to maintain target concentration levels. The control system uses sensor feedback to determine when pump activation is necessary, maintaining CSF flow consistency while minimizing energy consumption during idle periods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise and efficient delivery of therapeutic agents to specific anatomical locations within the subarachnoid space, reducing toxicity and the need for large drug volumes, and effectively penetrating the blood-brain barrier.
Implementation Method 1
The pump is energized to cause CSF to flow between the lumbar and ventricle of the patient
Implementation Method 2
The fluid channel has a catheter having a lumen configured to transport ASO mixed with CSF of the patient
Implementation Method 3
The fluid channel may form a closed loop configured to circulate CSF and ASO mixture through the ventricle, the body chambers through which CSF flows, the lumbar, and fluid channel
Data Source
AI summary
A method to regulate patient gene expression by controllably circulating antisense oligonucleotide material (ASO) through a closed fluid circuit formed between the patient's ventricle and lumbar regions. To that end, after coupling a fluid channel between those regions, such embodiments add ASO to the fluid channel (preferably after the channel is primed with CSF) and energize a pump to controllably flow the CSF and the ASO mixed with the CSF. CSF/ASO fluid flow may be managed to localize treatment (e.g., providing deep brain distribution) while minimizing toxicity potentially caused by the ASO to certain nerves (e.g., the peripheral nerve).